放射增敏联合肽受体放射性核素治疗高增殖性神经内分泌恶性肿瘤的初步临床证据
本研究纳入20例组织学确诊的胃肠胰神经内分泌肿瘤(GEP-NET)、Ki67在15%至55%之间的患者,其中10例仅接受肽受体放射性核素治疗(PRRT),另10例接受PRRT联合卡培他滨/替莫唑胺(CAP/TEM)至少连续2个周期。PRRT+CAP/TEM组的疾病控制率为90%,仅PRRT组为60%;两组不良事件无差异。
要点
- PRRT+CAP/TEM组疾病控制率90%(20%疾病稳定、70%部分缓解),仅PRRT组为60%(40%疾病稳定、20%部分缓解)。
- PRRT+CAP/TEM组中位无进展生存期为26个月,仅PRRT组为12个月;观察期内PRRT+CAP/TEM组该终点尚未全部达到。
- 两组全等级不良事件无差异,作者认为PRRT+CAP/TEM是高度有前景且耐受良好的方案,并认为需开展前瞻性随机临床试验。
核心结论
- PRRT+CAP/TEM对Ki67≥15%的生长抑素受体阳性NET患者是高度有前景且耐受良好的治疗方案,作者认为需开展前瞻性随机临床试验。
研究设计与样本
- 临床先导研究,纳入20例组织学确诊的胃肠胰神经内分泌肿瘤(GEP-NET)、增殖率(Ki67)在15%至55%之间的患者。
- 患者接受PRRT单药治疗(n=10)或PRRT联合卡培他滨/替莫唑胺(CAP/TEM)至少连续2个周期的联合治疗(n=10)。
主要发现
- 仅PRRT组疾病控制率为60%(40%疾病稳定、20%部分缓解),PRRT+CAP/TEM组为90%(20%疾病稳定、70%部分缓解)。
- 仅PRRT组中位无进展生存期为12个月,PRRT+CAP/TEM组为26个月,且观察期内该组尚未全部达到该终点。
- 仅PRRT组中位疾病特异性生存期为51个月,PRRT+CAP/TEM组该终点尚未达到。
- PRRT+CAP/TEM组基于SSTR-PET的代谢肿瘤体积和嗜铬粒蛋白A水平的下降显著高于仅PRRT组。
- 两组全等级不良事件无差异。
关键数值与推荐
- 研究纳入标准为组织学确诊的GEP-NET且Ki67在15%至55%之间。
- 联合治疗组接受PRRT联合卡培他滨/替莫唑胺(CAP/TEM)至少连续2个周期。
临床怎么用
- 作者认为PRRT+CAP/TEM对Ki67≥15%的生长抑素受体阳性NET患者是高度有前景且耐受良好的治疗方案,并认为需开展前瞻性随机临床试验。
局限性
- 原文为临床先导研究(clinical pilot study),样本量为20例。
- 作者在结论中提出需开展前瞻性随机临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM/INTRODUCTION: Peptide receptor radionuclide therapy (PRRT) represents a cornerstone of treatment regimens for patients with low proliferative neuroendocrine tumors (NETs). However, in patients experiencing somatostatin receptor-positive NET with higher proliferation rates, a value and potential therapeutic benefit of PRRT as part of multimodal treatment approaches and potentially with addition of radiosensitizing agents has not yet been established. PATIENTS AND METHODS: In this study, 20 patients with histologically confirmed gastroenteropancreatic (GEP) NET with proliferation rates (Ki67) between 15% and 55% were treated either with PRRT only (n = 10) or with a combination therapy (n = 10) comprising PRRT and capecitabine/temozolomide (CAP/TEM) for at least 2 consecutive cycles. RESULTS: Disease control rate in patients treated with PRRT alone was 60% (40% stable disease and 20% partial response). Strikingly, in patients treated with PRRT in combination with radiosensitization (CAP/TEM), the disease control rate was 90% (20% stable disease and 70% partial response). The median progression-free survival in the PRRT only group was 12 months, whereas the median progression-free survival in the PRRT + CAP/TEM group was 26 months and has not been yet reached for all patients in the group during the observation period. The median disease-specific survival for patients with PRRT alone was 51 months, whereas this end point was not yet reached in the PRRT + CAP/TEM group. Moreover, the PRRT + CAP/TEM group showed a significantly higher reduction of SSTR-PET-based metabolic tumor volume and chromogranin A levels compared with the PRRT only group. Importantly, adverse events of all grades did not differ between both groups. CONCLUSIONS: PRRT + CAP/TEM represents a highly promising and well-tolerated therapeutic regimen for patients experiencing somatostatin receptor-positive NET with higher (Ki67 ≥ 15%) proliferation rate. Prospective randomized clinical trials are warranted.
引用
- Trautwein NF, Hinterleitner C, Kiefer LS, et al. Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot Study. Clin Nucl Med. 2024. PMID: 38271237. doi:10.1097/RLU.0000000000005006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。